Announcements Trials

Browse Landscape

Phase

Phase 2 20 Phase 1 7 Phase 3 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

pembrolizumab 210 Cyclophosphamide 123 Nivolumab 108 Carboplatin 92 fludarabine 82 Gemcitabine 77 Specimen Handling 74 Bevacizumab 72 venetoclax 70 Injections 70 Magnetic Resonance Spectroscopy 67 Dexamethasone 66 Paclitaxel 65 Biopsy 59 atezolizumab 56 Cisplatin 55 Ipilimumab 50 Temozolomide 45 Docetaxel 43 Azacitidine 42 Oxaliplatin 41 Lenalidomide 41 Pemetrexed 40 Fluorouracil 40 Rituximab 39 Radiotherapy 39 Cetuximab 37 Capecitabine 37 durvalumab 36 Cytarabine 36

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × ceralasertib × 1 year × Clear all

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡